WellPoint NextRx pilots over-the-counter medication program with Blue Cross & Blue Shield of Rhode Island

News
Article

WellPoint Next Rx pilots OTC generic program with Blue Cross & Blue Shield of Rhode Island to help offset out-of-pocket costs for members.

Related Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
Dr. Charles Lee
Related Content
FDA Roundup: Generic Naloxone, Pediatric Low-Grade Glioma Treatment

FDA Roundup: Generic Naloxone, Pediatric Low-Grade Glioma Treatment

April 26th 2024
Article

Check out important updates from the FDA for the week of April 22.

Looking to the Future of Independent Pharmacy

Looking to the Future of Independent Pharmacy

July 13th 2022
Podcast

Don Arthur, RPh, discusses what lays ahead in independent pharmacy, from clinical care to success stories.

FDA Approves Generic OTC Naloxone Nasal Spray

FDA Approves Generic OTC Naloxone Nasal Spray

April 25th 2024
Article

Amneal Pharmaceuticals said its generic naloxone hydrochloride nasal spray is now available in the US following FDA approval.

Podcast: Pharmacy Financing With First Financial Bank

Podcast: Pharmacy Financing With First Financial Bank

January 28th 2022
Podcast

Learn more about the ins and outs of pharmacy ownership from the experts at First Financial Bank.

FDA Issues CRL for Epidermolysis Bullosa Gene Therapy

FDA Issues CRL for Epidermolysis Bullosa Gene Therapy

April 23rd 2024
Article

Abeona Therapeutics’ pz-cel is an investigational autologous, COL7A1 gene-corrected epidermal sheet therapy for the treatment of recessive dystrophic epidermolysis bullosa.

FDA Roundup: Biosimilars, Boxed Warning Added for CAR T-Cell Therapies

FDA Roundup: Biosimilars, Boxed Warning Added for CAR T-Cell Therapies

April 19th 2024
Article

Check out important updates from the FDA for the week of April 15.

© 2024 MJH Life Sciences

All rights reserved.